Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944066 | 1.00 | KMT2A (0.62) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL1409248 | 0.86 | HSP90AA1 (0.53) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL1409250 | 0.86 | HSP90AA1 (0.53) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL947656 | 0.84 | ALDH1A1 (0.54) | KMT2AMEN1GAAS1PR1S1PR3 | |
| SCHEMBL947654 | 0.84 | ALDH1A1 (0.54) | KMT2AMEN1GAAS1PR1S1PR3 | |
| SCHEMBL948192 | 0.84 | MGLL (0.55) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL948194 | 0.84 | MGLL (0.55) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL16621583 | 0.82 | KMT2A (0.43) | KMT2AMEN1GAAMGLLS1PR1 | |
| SCHEMBL948141 | 0.82 | MEN1 (0.47) | KMT2AMEN1GAAL3MBTL1ALDH1A1 | |
| SCHEMBL948142 | 0.82 | MEN1 (0.47) | KMT2AMEN1GAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | claimed |
| EP-2094676-B1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINOTHIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | claimed |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | claimed |
| EP-2489662-A1 | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | Actelion Pharmaceuticals Ltd. (CH) | 2012-08-22 | — | — | EP | claimed |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | VANDA PHARMACEUTICALS INC. | 2011-08-18 | — | — | US | claimed |
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-16 | — | — | US | claimed |
| JP-2010510976-A | — | — | 2010-04-08 | — | — | JP | claimed |
| EP-2094676-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008062376-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | claimed |
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| EP-1689726-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054215-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054215-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | KMT2A 4219/4885MEN1 690/4885GAA 2877/4885 |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | IL4, IL2, IL15 | KMT2A 3869/4885MEN1 415/4885GAA 3294/4885 |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | TLR4, IL4, IRF3 | KMT2A 3946/4885MEN1 3791/4885GAA 1814/4885 |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | KMT2A 4219/4885MEN1 690/4885GAA 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.